Kết quả tìm kiếm - Yuanlong Lin

  • Đang hiển thị 1 - 7 kết quả của 7
Tinh chỉnh kết quả
  1. 1
    Circulating levels of IL‐2, IL‐4, TNF‐α, IFN‐γ, and C‐reactive protein are not associated with severity of COVID‐19 symptoms

    Circulating levels of IL‐2, IL‐4, TNF‐α, IFN‐γ, and C‐reactive protein are not associated with severity of COVID‐19 symptoms Bằng Wen Luo, Jiawen Zhang, Wei Zhang, Yuanlong Lin, Qi Wang

    Được phát hành 2020
    lấy văn bản
    Carta
    Lưu vào danh sách
    Đã lưu trong:
  2. 2
    Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial

    Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical... Bằng Jiangtao Bai, Tetsuya Asakawa, Wenfang Yuan, Yuanlong Lin, Hao Ju, Dandan Xu, Mingming Yang, Shuo Li, Guanguan Li, Deyin Guo, Hongzhou Lu, Xumu Zhang

    Được phát hành 2025
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  3. 3
    Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees

    Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees Bằng Yangyang, Xiaohua Gong, Liuqing Yang, Jie Li, Jiaqi Zhang, Lanlan Wei, Guoguo Ye, Yimin Tang, Yujing Jiang, Jianhuan Li, Yuanlong Lin, Fuxiang Wang, Hongzhou Lu, Yingxia Liu

    Được phát hành 2022
    lấy văn bản
    Carta
    Lưu vào danh sách
    Đã lưu trong:
  4. 4
    Evolutionary trajectory and characteristics of Mpox virus in 2023 based on a large-scale genomic surveillance in Shenzhen, China

    Evolutionary trajectory and characteristics of Mpox virus in 2023 based on a large-scale genomic surveillance in Shenzhen, China Bằng Shengjie Zhang, Fuxiang Wang, Yun Peng, Xiaohua Gong, Guohao Fan, Yuanlong Lin, Liuqing Yang, Liang Shen, Shiyu Niu, J. Liu, Yue Yin, Jing Yuan, Hongzhou Lu, Yingxia Liu, Yang Yang

    Được phát hành 2024
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  5. 5
    Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial

    Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial Bằng Hongzhou Lu, George Zhang, John Mao, Xiaochun Chen, Yangqing Zhan, Ling Lin, Tianxiang Zhang, Yanan Tang, Feng Lin, Feiyue Zhu, Yuanlong Lin, Yiming Zeng, Kaiyu Zhang, Wenfang Yuan, Zhenyu Liang, Ruilin Sun, L. Huo, Peng Hu, Yihua Lin, Xibin Zhuang, Zhaohui Wei, Xia Chen, Wenhao Yan, Xiu‐Ping Yan, L.M. Mu, Zhuhua Lin, Xinyu Tu, Hongshan Tan, Fuhu Huang, Zhiqiang Hu, Hongming Li, Guoping Li, Haijun Fu, Zifeng Yang, Xinwen Chen, Fu‐Sheng Wang, Nanshan Zhong

    Được phát hành 2024
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  6. 6
    Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19

    Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19 Bằng Long Mao, Namir Shaabani, Xiaoying Zhang, Can Jin, Wanhong Xu, Christopher Argent, Yulia Kushnareva, Colin Powers, Karen Stegman, Jia Liu, Huimin Xie, Changxu Xu, Yimei Bao, Lijun Xu, Yuren Zhang, Haigang Yang, Shengdian Qian, Yong Hu, Jianping Shao, Can Zhang, Tingting Li, Yi Li, Na Liu, Zhenhao Lin, Shanbo Wang, Chao Wang, Weiliang Shen, Yuanlong Lin, Dan Shu, Zhenhong Zhu, Olivia Kotoi, Lisa Kerwin, Qing Han, Ludmila Chumakova, John R. Teijaro, Mike A. Royal, Mark Brunswick, Robert D. Allen, Henry Ji, Hongzhou Lu, Xiaohong Xu

    Được phát hành 2024
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  7. 7
    Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial

    Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial Bằng Huijie Bian, Chen Liang, Zheng Zhang, Aidong Wen, Zhaohui Zheng, Liqiang Song, Mengying Yao, Yingxia Liu, Xijing Zhang, Honglin Dong, Jianqi Lian, Lei Pan, Yu Liu, Xing Gu, Hui Zhao, Jingwen Wang, Qingyi Wang, Kui Zhang, Junfeng Jia, Xie Rong-hua, Xing Luo, Xianghui Fu, Yanyan Jia, Junna Hou, Qiuyue Tan, Xiaoxia Chen, Liuqing Yang, Yuanlong Lin, Xiaoxia Wang, Lei Zhang, Qingfeng Zeng, Wenjie Li, Ruixuan Wang, Yang Zhang, Xiuxuan Sun, Bin Wang, Yang Xu, Jian-Li Jiang, Ling Li, Jiao Wu, Xiang-Min Yang, Hai Feng Zhang, Ying Shi, Xiaochun Chen, Hao Tang, Hongwei Shi, Shuangshuang Liu, Yong Yang, Tianyi Yang, Wei Ding, Zhi‐Nan Chen, Ping Zhu

    Được phát hành 2025
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: